Difference between revisions of "Bleomycin (Blenoxane)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
Warner-admin (talk | contribs) m |
||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[Basal cell | + | *[[Adenocarcinoma of unknown primary]] |
| + | *[[Basal cell carcinoma (BCC)]] | ||
*[[Diffuse large B-cell lymphoma]] | *[[Diffuse large B-cell lymphoma]] | ||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
| Line 17: | Line 18: | ||
*[[Penile cancer]] | *[[Penile cancer]] | ||
*[[Post-transplant lymphoproliferative disorder]] | *[[Post-transplant lymphoproliferative disorder]] | ||
| − | |||
*[[Testicular cancer]] | *[[Testicular cancer]] | ||
| − | *[[ | + | *[[Vascular sarcoma]] |
==Patient drug information== | ==Patient drug information== | ||
| Line 44: | Line 44: | ||
[[Category:DNA synthesis inhibitors]] | [[Category:DNA synthesis inhibitors]] | ||
| + | [[Category:Adenocarcinoma of unknown primary medications]] | ||
[[Category:Basal cell carcinoma (BCC) medications]] | [[Category:Basal cell carcinoma (BCC) medications]] | ||
| − | |||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
[[Category:HIV-associated lymphoma medications]] | [[Category:HIV-associated lymphoma medications]] | ||
| Line 53: | Line 53: | ||
[[Category:Penile cancer medications]] | [[Category:Penile cancer medications]] | ||
[[Category:Post-transplant lymphoproliferative disorder medications]] | [[Category:Post-transplant lymphoproliferative disorder medications]] | ||
| − | |||
[[Category:Testicular cancer medications]] | [[Category:Testicular cancer medications]] | ||
| + | [[Category:Vascular sarcoma medications]] | ||
[[Category:Drugs FDA approved in 1973]] | [[Category:Drugs FDA approved in 1973]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 02:48, 24 January 2018
General information
Class/mechanism: Exact mechanism unknown, but suspected to inhibit DNA synthesis, with some evidence inhibition of RNA and protein synthesis. When administered intrapleurally for malignant pleural effusion, bleomycin acts as a sclerosing agent.[1]
Route: IV, IM, SC, intrapleural
Extravasation: irritant or neutral, depending on reference
- 1 unit of bleomycin = 1 mg of bleomycin
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adenocarcinoma of unknown primary
- Basal cell carcinoma (BCC)
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Osteosarcoma
- Penile cancer
- Post-transplant lymphoproliferative disorder
- Testicular cancer
- Vascular sarcoma
Patient drug information
- Bleomycin (Blenoxane) patient drug information (Chemocare)[2]
- Bleomycin (Blenoxane) patient drug information (UpToDate)[3]
History of changes in FDA indication
- 7/31/1973: Initial FDA approval
Also known as
- Brand names: Blenoxane, Bleo, Bleocin, Bleocip, Bleopar, Bleowel
References
Categories:
- Drug index
- Intracavitary medications
- Intramuscular medications
- Intravenous medications
- Subcutaneous medications
- Irritant chemotherapy
- Neutral chemotherapy
- DNA synthesis inhibitors
- Adenocarcinoma of unknown primary medications
- Basal cell carcinoma (BCC) medications
- Diffuse large B-cell lymphoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Osteosarcoma medications
- Penile cancer medications
- Post-transplant lymphoproliferative disorder medications
- Testicular cancer medications
- Vascular sarcoma medications
- Drugs FDA approved in 1973
- WHO Essential Cancer Medicine